JP2022536613A5 - - Google Patents
Info
- Publication number
- JP2022536613A5 JP2022536613A5 JP2021570726A JP2021570726A JP2022536613A5 JP 2022536613 A5 JP2022536613 A5 JP 2022536613A5 JP 2021570726 A JP2021570726 A JP 2021570726A JP 2021570726 A JP2021570726 A JP 2021570726A JP 2022536613 A5 JP2022536613 A5 JP 2022536613A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- acid sequence
- apoe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025039014A JP2025094005A (ja) | 2019-05-28 | 2025-03-12 | ＡｐｏＥ抗体、融合タンパク質、およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853676P | 2019-05-28 | 2019-05-28 | |
| US62/853,676 | 2019-05-28 | ||
| US201962873019P | 2019-07-11 | 2019-07-11 | |
| US62/873,019 | 2019-07-11 | ||
| PCT/US2020/034978 WO2020243346A1 (en) | 2019-05-28 | 2020-05-28 | Apoe antibodies, fusion proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025039014A Division JP2025094005A (ja) | 2019-05-28 | 2025-03-12 | ＡｐｏＥ抗体、融合タンパク質、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536613A JP2022536613A (ja) | 2022-08-18 |
| JP2022536613A5 true JP2022536613A5 (https=) | 2023-06-05 |
| JP7750745B2 JP7750745B2 (ja) | 2025-10-07 |
Family
ID=73553546
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570726A Active JP7750745B2 (ja) | 2019-05-28 | 2020-05-28 | ＡｐｏＥ抗体、融合タンパク質、およびその使用 |
| JP2025039014A Pending JP2025094005A (ja) | 2019-05-28 | 2025-03-12 | ＡｐｏＥ抗体、融合タンパク質、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025039014A Pending JP2025094005A (ja) | 2019-05-28 | 2025-03-12 | ＡｐｏＥ抗体、融合タンパク質、およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US12384834B2 (https=) |
| EP (1) | EP3976642A4 (https=) |
| JP (2) | JP7750745B2 (https=) |
| CN (2) | CN114174330B (https=) |
| AU (2) | AU2020282792B2 (https=) |
| CA (1) | CA3141988A1 (https=) |
| WO (1) | WO2020243346A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| AU2020282792B2 (en) * | 2019-05-28 | 2025-12-04 | Banner Health | ApoE antibodies, fusion proteins and uses thereof |
| EP4065600A1 (en) * | 2019-11-25 | 2022-10-05 | Cornell University | Apoe gene therapy |
| US20220127347A1 (en) * | 2020-10-26 | 2022-04-28 | The Regents Of The University Of California | Inhibition of Tau Propagation |
| CA3243602A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
| CN121358763A (zh) * | 2023-06-15 | 2026-01-16 | Rnagene公司 | 包括载脂蛋白质或其片段的融合蛋白质和其用途 |
| CN117603916B (zh) * | 2023-11-17 | 2024-07-23 | 赛业（苏州）生物科技有限公司 | 一种基于全人源化抗体鼠的人b7-h3抗体及其制备方法和应用 |
| WO2025245146A2 (en) * | 2024-05-20 | 2025-11-27 | Nextcure, Inc. | Anti-apoe antibodies: compositions and methods of making and using the same |
| EP4685158A1 (en) * | 2024-07-22 | 2026-01-28 | Technische Universität München | Fibrillary apolipoprotein e (apoe) for use in a method of treatment and/or prevention of a neurodegenerative disease |
| CN119529080A (zh) * | 2024-11-20 | 2025-02-28 | 中元汇吉生物技术股份有限公司 | 抗ApoE4抗体或其功能性片段及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| JP3265577B2 (ja) | 1992-10-13 | 2002-03-11 | デューク・ユニバーシティ | アポリポ蛋白ｅの４型イソ型の測定法 |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7964598B2 (en) * | 1995-10-17 | 2011-06-21 | The J. David Gladstone Institutes | ApoE4 domain interaction inhibitors and methods of use thereof |
| DE60042338D1 (de) | 1999-10-04 | 2009-07-16 | Univ New Jersey Med | TAR RNA bindende Peptide |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| RU2006122946A (ru) | 2003-11-28 | 2008-01-10 | Астразенека Аб (Se) | Антитела |
| US7612179B2 (en) * | 2003-11-28 | 2009-11-03 | Astrazeneca Ab | antibodies binding to a C-terminal fragment of apoliopoprotein E |
| JP5055293B2 (ja) * | 2005-12-07 | 2012-10-24 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | ミトコンドリア機能を調節する物質を同定する方法 |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| MX2013006116A (es) * | 2010-12-02 | 2013-10-17 | Univ Washington | Tratamiento de sintomas asociados a placa amiloide. |
| JP2014511174A (ja) * | 2011-02-07 | 2014-05-15 | ネオトープ バイオサイエンシーズ リミテッド | Ａｐｏｅ免疫療法 |
| WO2013181618A2 (en) * | 2012-05-31 | 2013-12-05 | The Trustees Of Columbia University In The City Of New York | Methods to treat alzheimer's disease using apoe inhibitors |
| CN106232618A (zh) | 2013-10-11 | 2016-12-14 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
| BR112019001887A2 (pt) | 2016-08-02 | 2019-07-09 | Editas Medicine Inc | composições e métodos para o tratamento de doença associada a cep290 |
| EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| CA3042236A1 (en) * | 2016-10-28 | 2018-05-03 | Washington University | Anti-apoe antibodies |
| EP3668551A4 (en) * | 2017-08-15 | 2021-04-14 | Children's Medical Center Corporation | APOM FC FUSION PROTEINS AND USES THEREOF |
| EP3774866A1 (en) * | 2018-04-13 | 2021-02-17 | Ludwig Institute for Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
| AU2020282792B2 (en) * | 2019-05-28 | 2025-12-04 | Banner Health | ApoE antibodies, fusion proteins and uses thereof |
-
2020
- 2020-05-28 AU AU2020282792A patent/AU2020282792B2/en active Active
- 2020-05-28 CA CA3141988A patent/CA3141988A1/en active Pending
- 2020-05-28 EP EP20815122.5A patent/EP3976642A4/en active Pending
- 2020-05-28 WO PCT/US2020/034978 patent/WO2020243346A1/en not_active Ceased
- 2020-05-28 CN CN202080054661.6A patent/CN114174330B/zh active Active
- 2020-05-28 CN CN202510000560.5A patent/CN120098122A/zh active Pending
- 2020-05-28 US US17/614,008 patent/US12384834B2/en active Active
- 2020-05-28 JP JP2021570726A patent/JP7750745B2/ja active Active
-
2024
- 2024-03-20 US US18/611,374 patent/US20240301044A1/en active Pending
- 2024-03-20 US US18/611,325 patent/US20240287165A1/en active Pending
-
2025
- 2025-03-12 JP JP2025039014A patent/JP2025094005A/ja active Pending
-
2026
- 2026-02-27 AU AU2026201500A patent/AU2026201500A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536613A5 (https=) | ||
| JP7780158B2 (ja) | ＲＧＭａ結合タンパク質及びその使用 | |
| JP6431615B2 (ja) | タウに対する抗体およびその使用 | |
| KR20210005169A (ko) | 최적화된 항tl1a 항체 | |
| US20220273779A1 (en) | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies | |
| TWI843040B (zh) | 抗N3pGlu類澱粉β抗體及其用途 | |
| CA3141988A1 (en) | Apoe antibodies, fusion proteins and uses thereof | |
| WO2013063516A1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| JP7760626B2 (ja) | 治療に使用するための抗ソルチリン抗体 | |
| TWI799840B (zh) | 靶向介白素-34之化合物及方法 | |
| CA3228359A1 (en) | Methods of treating tau pathologies | |
| EP3873934A2 (en) | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport | |
| CN113874078B (zh) | 抗tauc3抗体及其应用 | |
| KR20240035835A (ko) | 항-angptl3 항체 또는 이의 항원 결합 단편의 약학적 조성물 및 이의 응용 | |
| CN118184778A (zh) | 一种AD7c-NTP单克隆抗体及其应用 | |
| US20230250191A1 (en) | Anti-ige engineered antibody and application thereof | |
| US20230331863A1 (en) | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease | |
| CN118201637A (zh) | 治疗Tau病理的方法 | |
| HK40112634A (zh) | 治疗tau病理的方法 | |
| TW202334212A (zh) | 靶向介白素-34之化合物及方法 | |
| TW202334211A (zh) | 靶向介白素-34之化合物及方法 | |
| TW202334210A (zh) | 靶向介白素-34之化合物及方法 |